The new SA article is a genius example of soft bashing with
The new SA article is a genius example of soft bashing with an agenda. It provides an opportunity for the bashers to pile in for comments (like the one saying "why would you invest in a company with a 50/50 chance of having to defend a lawsuit" -- an utter lie, the chance that the lawsuit will proceed is in my opinion minimal and is certainly much, much less than 50%). The article also bashes by saying "so what if management has funding, it will need cash to fund trials and will be forced to sell stock at a lowball price." They have absolutely NO basis to say that. Just because other companies had problems with the FDA wanting more studies absolutely does NOT mean that CTIX will run into the same thing. To claim that it will, and that CTIX will be forced to sell stock, is a dead lie.
The cries for a partnership at any price have been something that we've heard for at least TWO YEARS from the bashers at other sites. This is more of the same, much more skillfully presented.
And does that "Hey Leo" stuff sound familiar to anyone? Yep, the author is either one of the lieHUB bashers who posts under several names with the "Hey Leo" stuff, or else it's someone who has read lieHUB so much that it's become part of his/her way of expression.
It seems clearer than ever that some Big Pharma wants a partnership. And they want it cheap.
3
1
Innovation Pharmaceuticals Inc (IPIX) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Top 5 Most Recently Viewed Articles
SmartFinancial Announces Upcoming Earnings Release SmartFinancial, Inc. (NYSE: SMBK) has revealed important details regarding its Fourth Quarter earnings for the year 2024. This is an exciting time for investors and stakeholders as the company prepares to share insights into its financial performance. Earnings Release Date and Conference Call Information The earnings...
Continue Reading
IntouchCX Strengthens Trust and Safety Solutions Through Acquisition IntouchCX has recently made headlines with its acquisition of WebPurify, a leading provider of innovative content moderation solutions that harness the power of artificial intelligence. This strategic move represents a significant advancement in IntouchCX's mission to redefine Trust and Safety solutions,...
Continue Reading
Y-mAbs Therapeutics Engages Investors at Upcoming Conferences This September, Y-mAbs Therapeutics, Inc. (Nasdaq: YMAB), a key player in the biopharmaceutical industry, is poised to attract investor interest. The company is known for its innovative radioimmunotherapy and antibody-based treatments designed to transform cancer care. Michael Rossi, the energetic CEO of...
Continue Reading
Overview of CorVel's Financial Performance CorVel Corporation (NASDAQ: CRVL) recently unveiled impressive results for the quarter and fiscal year, showcasing strong revenue gains and enhanced earnings metrics. The quarterly revenue hit $232 million, a notable rise from $207 million compared to the same quarter last year. This upward trend is mirrored across the fiscal...
Continue Reading
IQAX eBL Interoperability Approval Highlights IQAX Limited has made significant strides in enhancing its electronic bill of lading (eBL) solution by receiving official approval from the International Group of P&I Clubs (IG P&I Clubs). This approval affirms the capabilities of IQAX eBL's interoperable addendum, empowering users to perform eBL transactions across different...
Continue Reading